Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9550 monotherapy and AZD9550 + AZD6234 multiple-ascending-dose study in adults with overweight or obesity, with or without type 2 diabetes
2023-504215-32-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 2, randomised, single-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing AZD9550 monotherapy, AZD9550 + AZD6234 and Placebo control (3 arms). Started Sep 2023; status: completed.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-504215-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504215-32-00.